Amgenvs.Incyte
AMGN vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 9.3× larger than Incyte by market cap; Incyte trades at the lower P/E (15.1 vs 25.8); year to date, Amgen leads (+35.6% vs +29.6%).
Side by side
| AMGN | INCY | |
|---|---|---|
| Market cap | $226B | $24.4B |
| Price | $442.24 | $129.72 |
| Today | −0.4% | +1.4% |
| Return YTD | +35.6% | +29.6% |
| Return 1Y | +51.1% | +50.5% |
| P/E | 25.8 | 15.1 |
| P/S | 5.9 | 4.2 |
| P/B | 19.3 | 3.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More AMGN & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.
See where AMGN and INCY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →